Shah Sanket M, Jain Ankitkumar S, Kaushik Ritu, Nagarsenker Mangal S, Nerurkar Maneesh J
Department of Pharmaceutics, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai, 400098, India.
AAPS PharmSciTech. 2014 Oct;15(5):1307-23. doi: 10.1208/s12249-014-0156-1. Epub 2014 Jun 12.
A lot of resources and efforts have been directed to synthesizing potentially useful new chemical entities (NCEs) by pharmaceutical scientists globally. Detailed physicochemical characterization of NCEs in an industrial setup begins almost simultaneously with preclinical testing. Most NCEs possess poor water solubility posing bioavailability issues during initial preclinical screening, sometimes resulting in dropping out of an NCE with promising therapeutic activity. Selection of right formulation approach for an NCE, based on its physicochemical properties, can aid in improving its solubility-related absorption and bioavailability issues. The review focuses on preclinical formulations stressing upon different preclinical formulation strategies and deciphers the understanding of formulation approaches that could be employed. It also provides detailed information related to a vast pool of excipients available today, which is of immense help in designing preclinical formulations. Few examples mentioned, throw light on key aspects of preclinical formulation development. The review will serve as an important guide for selecting the right strategy to improve bioavailability of NCEs for academic as well as industrial formulation scientists.
全球制药科学家投入了大量资源和精力来合成潜在有用的新化学实体(NCE)。在工业环境中,NCE的详细物理化学表征几乎与临床前测试同时开始。大多数NCE的水溶性较差,在初始临床前筛选期间会出现生物利用度问题,有时会导致具有潜在治疗活性的NCE被淘汰。根据NCE的物理化学性质选择合适的制剂方法,有助于改善其与溶解度相关的吸收和生物利用度问题。本综述重点关注临床前制剂,强调不同的临床前制剂策略,并解读可采用的制剂方法。它还提供了与当今大量可用辅料相关的详细信息,这对设计临床前制剂有极大帮助。文中提到的一些例子阐明了临床前制剂开发的关键方面。本综述将为学术和工业制剂科学家选择提高NCE生物利用度的正确策略提供重要指导。